Arrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growth
ARWR•Outlook
The company plans to submit a plozasiran sNDA before the end of 2026 to expand approved indications. Arrowhead expects YOSEMITE Phase 3 trial completion in mid-2027, with regulatory filings to follow.
The company sees continued commercial momentum for REDEMPLO with expanding market access and physician adoption.
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $100.00, about 16.3% above its August 3 closing price of $86.01.
Quarterly results
Arrowhead Pharmaceuticals' fiscal third-quarter revenue rose sharply, beating analyst expectations, as REDEMPLO growth helped offset a wider net loss.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q3 Revenue | Beat | $75.25 mln | $54.29 mln (9 Analysts) |
| Q3 Loss Per Share | $1.36 | ||
| Q3 Operating Expenses | $245.35 mln | ||
| Q3 Operating Income | -$170.09 mln |
Growth drivers and licensing payment
REDEMPLO growth was a key driver of the quarter. The company said U.S. REDEMPLO prescription volume roughly doubled in the quarter and payer coverage expanded, with new marketing authorizations in Europe and Australia.
